Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood pressure drugs may slow brain damage in seniors

NCT ID NCT02472028

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether lowering blood pressure can slow the growth of white matter lesions in the brains of older adults (60-88) with high blood pressure and memory complaints. About 820 participants will receive either standard care or an enhanced blood pressure lowering strategy using common medications. The goal is to see if better blood pressure control can preserve brain health over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood pressure lowering drugs (diuretics, beta-blockers, ACE inhibitors, ARBs, calcium channel blockers)
What this could lead to
If successful, this could show that controlling blood pressure helps preserve brain health and slow cognitive decline in older adults.
What could go wrong
This is a Phase 4 study, but results may not apply to all older adults. Blood pressure medications can cause side effects like dizziness or falls.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 820 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2015

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 88 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 60 to 88 years old patients; * Patient with cognitive complaint with MMSE ≥ 20performed within 6 months prior to enrollment (with or without dementia) * Patient with a socio-educational level ≥ 3 * Presence of hyperintensities of moderate to high grade on the last MRI or old scan (grades C and D on the modified Scheltens scale, grades 2/3 Fazekas). * Hypertension defined by a Systolic Blood Pressure (SBP) and / or a Diastolic Blood Pressure (DBP) ≥ 140/90 mmHg, treated or not * Affiliation to a social security system * Informed consent given, signed consent Exclusion Criteria: * Presence of severe orthostatic hypotension defined as a decrease of 30 mmHg in SBP standing within 3 minutes * Contraindication to MRI (presence of ferromagnetic foreign body (especially some intracranial clips, some heart valves, intraocular foreign bodies, metal prosthesis), subject carrying pacemaker, claustrophobic participants) * Severe diseases associated with a life expectancy of less than 3 months; * Major physical impairments that can interfere with the feasibility of the tests (sight, hearing ...) * Presence of another dementia different than Alzheimer's disease vascular dementia or mixed dementia, * Persons under guardianship; * Secondary hypertension: renovascular hypertension, primary aldosteronism, pheochromocytoma ...; * Patient already receiving 4 or more antihypertensive drugs at maximum dosage * Patient participating in another clinical research study on drug requiring exclusion period * severe renal impairment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebrovascular disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebrovascular disorder Memory Disorders stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebrovascular disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Memory Resources Centre and South of Ile de France Search - Broca Hospital

    RECRUITING

    Paris, 75013, France

  • Memory for Research and Resources Center / Neuroscience pole

    NOT_YET_RECRUITING

    Bordeaux, Pellegrin Hospital Group, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.